EHA 2022 | The impact of SF3B1 mutations in myelofibrosis
Jayastu Senapati
• 13 Jun 2022
Jayastu Senapati, MBBS, MD, MD Anderson Cancer Center, Houston, TX, describes the findings of a study evaluating the impact of SF3B1 mutations in patients with myelofibrosis (MF). The study found that a higher proportion of patients carrying mutations in SF3B1 were transfusion-dependent and a lower proportion of these patients had grade 3 bone marrow fibrosis. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
